Oxygen nanobubbles revert hypoxia by methylation programming

Area of Science:

• Oncology
• Nanotechnology
• Epigenetics

Background:

• Hypoxic tumor microenvironments promote cancer progression and therapeutic resistance.
• Epigenetic alterations, such as 5-methylcytosine (5mC) hypomethylation, are critical in hypoxia-driven cancers.
• Targeting tumor hypoxia is a key strategy in cancer therapeutics.

Purpose of the Study:

• To develop and evaluate oxygen-encapsulated nanobubbles for mitigating tumor hypoxia.
• To investigate the potential of oxygen nanobubbles in reversing epigenetic dysregulation in hypoxic tumors.
• To assess the therapeutic efficacy of oxygen nanobubbles in preclinical cancer models.

Main Methods:

• Fabrication of sub-100 nm oxygen-encapsulated carboxymethyl cellulosic nanobubbles.
• In vitro and in vivo evaluation of nanobubble efficacy in hypoxic tumor models.
• Analysis of DNA methylation patterns (5mC) and gene expression (BRCA1, MAT2A, PDK-1) following nanobubble treatment.
• Assessment of tumor growth inhibition and survival rates in mice.

Main Results:

• Oxygen nanobubbles effectively mitigated hypoxic regions in tumors.
• Reversion of 5-methylcytosine (5mC) hypomethylation was observed in hypoxic tumor areas.
• Significant hypermethylation in the BRCA1 promoter region and reprogramming of hypoxia-associated genes (MAT2A, PDK-1) were noted.
• Oxygen nanobubbles significantly delayed tumor progression and improved survival rates in mice.
• Nanobubbles demonstrated utility as ultrasound contrast agents.

Conclusions:

• Nanosized oxygen-filled bubbles represent a promising strategy for epigenetic reprogramming in cancer therapy.
• This approach targets tumor hypoxia to reverse detrimental epigenetic changes and inhibit tumor growth.
• Oxygen nanobubbles show potential as an adjuvant therapy with dual functionality as an ultrasound contrast agent.